Quest Partners LLC Purchases Shares of 6,669 Immunome, Inc. (NASDAQ:IMNM)

Quest Partners LLC acquired a new position in Immunome, Inc. (NASDAQ:IMNM) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 6,669 shares of the company’s stock, valued at approximately $81,000.

A number of other hedge funds have also recently made changes to their positions in IMNM. Avidity Partners Management LP acquired a new position in Immunome in the 4th quarter valued at about $14,268,000. Mayo Clinic acquired a new position in shares of Immunome in the fourth quarter valued at approximately $1,161,000. Lord Abbett & CO. LLC purchased a new stake in Immunome during the 1st quarter worth approximately $10,994,000. Swiss National Bank acquired a new stake in Immunome during the 1st quarter worth approximately $1,762,000. Finally, Cetera Investment Advisers purchased a new position in Immunome in the 1st quarter valued at approximately $3,038,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on IMNM. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Tuesday, August 13th. Piper Sandler lowered their target price on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome presently has a consensus rating of “Buy” and a consensus target price of $29.00.

Insider Buying and Selling

In other Immunome news, insider Jack Higgins sold 3,524 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total value of $49,089.32. Following the transaction, the insider now directly owns 16,000 shares in the company, valued at $222,880. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Immunome news, insider Jack Higgins sold 3,524 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $13.93, for a total transaction of $49,089.32. Following the transaction, the insider now owns 16,000 shares of the company’s stock, valued at $222,880. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jean Jacques Bienaime bought 7,000 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were purchased at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the transaction, the director now directly owns 16,615 shares of the company’s stock, valued at approximately $231,613.10. The disclosure for this purchase can be found here. 8.60% of the stock is owned by company insiders.

Immunome Trading Down 2.5 %

Immunome stock opened at $15.40 on Wednesday. The company has a fifty day simple moving average of $14.34 and a 200-day simple moving average of $16.32. The stock has a market cap of $923.52 million, a P/E ratio of -2.04 and a beta of 1.77. Immunome, Inc. has a 12-month low of $6.65 and a 12-month high of $30.96.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). The business had revenue of $2.36 million for the quarter, compared to analysts’ expectations of $2.62 million. Immunome had a negative return on equity of 38.19% and a negative net margin of 2,435.02%. As a group, sell-side analysts forecast that Immunome, Inc. will post -1.92 earnings per share for the current fiscal year.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.